MAP2K7 and melanoma: Since 2011, the treatment landscape for advanced melanoma has evolved rapidly, with the introduction of the first immune checkpoint inhibitor (ICI) and v‐raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor in 2011, and mitogen‐activated protein kinase kinase (MEK) inhibitor in 2013.